Core Insights - The company has changed its name to Channel Therapeutics Corporation to better reflect its focus on sodium channel modulation and blockade for pain treatment [1][2] - The company has reincorporated in Nevada, expecting lower tax rates and increased strategic flexibility [4] Therapeutic Program Update - The Depot Program for Postoperative Nerve Blocks has shown sustained drug release over 96 hours in animal studies, with efficacy results expected imminently [5] - The Eye Pain Program has well-tolerated eye drops in animal studies, with efficacy results anticipated in the coming weeks and toxicology data expected by late Q1 2025, aiming to start Phase II human studies in Q2 2025 [5] - The company is exploring financing for its Chronic Pain program, expected to kick off in Q1 2025 [6] Company Overview - Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing non-opioid, non-addictive therapeutics targeting the sodium ion-channel NaV1.7 for various pain types [7]
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates